Moran Wealth Management Boosts DexCom Stake by 26.5%

The investment firm increased its holdings in the medical device company during Q4 2025.

Apr. 18, 2026 at 11:25am

Got story updates? Submit your updates here. ›

A high-contrast, black and white close-up image of the intricate inner workings and machinery of a continuous glucose monitoring device, conveying the technical sophistication of DexCom's medical technology.An extreme close-up of the complex mechanisms behind DexCom's innovative continuous glucose monitoring technology, signaling the company's engineering prowess and institutional investor confidence.San Diego Today

Moran Wealth Management LLC boosted its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 26.5% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund now owns 194,005 shares of the medical device company's stock, valued at $12.9 million.

Why it matters

DexCom is a leading manufacturer of continuous glucose monitoring (CGM) systems, which are critical devices for diabetes management. Institutional investors like Moran Wealth increasing their stakes in the company signals confidence in DexCom's growth potential and the continued adoption of its innovative CGM technology.

The details

Several other large investors also recently added to or reduced their stakes in DexCom. Brighton Jones LLC boosted its position by 257.7%, while Integrated Wealth Concepts LLC, Empowered Funds LLC, and NewEdge Advisors LLC also increased their holdings in the medical device company.

  • Moran Wealth Management's increased stake was reported in the firm's Q4 2025 13F filing.
  • The filing covers the three-month period ending December 31, 2025.

The players

Moran Wealth Management LLC

An investment management firm that boosted its stake in DexCom by 26.5% in Q4 2025.

DexCom, Inc.

A medical device company that develops and manufactures continuous glucose monitoring systems for people with diabetes.

Got photos? Submit your photos here. ›

The takeaway

DexCom's growing institutional investor base signals confidence in the company's market-leading CGM technology and its potential for continued growth as diabetes management evolves.